Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215520 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
A Phase 2 study of COVID-19, sponsored by CastleVax.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT07215520: Recruiting Phase 2 study of COVID-19, sponsored by CastleVax.
NCT07215520 is a Phase 2 study of COVID-19 that is actively recruiting participants, run by CastleVax. The registered enrollment target is 200 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07215520, a Phase 2 study of COVID-19, is actively recruiting participants, sponsored by CastleVax.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Double-blind, Randomized, Controlled, Phase 2a Study to Evaluate the Safety and Tolerability of a Newcastle Disease Virus-based Mucosal Vaccine (NDV-HXP-S-KP.2) Relative to an Approved Systemic mRNA Vaccine in Previously Vaccinated Adults
Primary Outcome
Safety and tolerability of the NDV-HXP-S-KP.2 vaccine given intranasally and an approved mRNA COVID-19 vaccine given intramuscularly will be assessed in previously immunized adults. Outcomes include the percentage of participants with solicited local and systemic reactogenicity symptoms through 7 days, unsolicited adverse events through 30 days, and serious, medically attended, or special interest adverse events through 180 days. Clinically significant abnormal lab results (chemistry and hematol
Conditions Studied
Interventions
- BIOLOGICAL NDV-HXP-S-KP.2
- BIOLOGICAL COVID-19 mRNA Vaccine
Study Locations (2)
Colorado
- Skylight Health Research - Colorado Springs
Massachusetts
- Skylight Health Research - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2026-08-19 |
| Phase | Phase 2 |
What NCT07215520 shows while recruiting
NCT07215520 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which NDV-HXP-S-KP.2 is the first listed.
NCT07215520 reports a single indexed study location in Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07215520 about?
NCT07215520 is a clinical study titled "Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults". A Double-blind, Randomized, Controlled, Phase 2a Study to Evaluate the Safety and Tolerability of a Newcastle Disease Virus-based Mucosal Vaccine (NDV-HXP-S-KP.2) Relative to an Approved Systemic mRNA Vaccine in Previously Vaccinated Adults
What is the current status of trial NCT07215520?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-11-03. Estimated completion is 2026-08-19.
What conditions does trial NCT07215520 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT07215520?
The interventions under investigation include: NDV-HXP-S-KP.2 (BIOLOGICAL), COVID-19 mRNA Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07215520?
This trial is sponsored by CastleVax, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07215520 being conducted?
This trial has 2 study locations across Colorado, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07215520's enrollment target sits among peer trials
200 161st of 298 higher than 138 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
-
Convalescent Plasma as a Possible Treatment for COVID-19
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI